Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.